洛索洛芬钠片联合关节腔内注射玻璃酸钠治疗骨关节炎的临床研究

发布时间：2019-07-08 10:37

【摘要】：目的观察洛索洛芬钠联合玻璃酸钠关节腔内注射治疗骨关节炎(OA)的临床疗效。方法将90例OA患者随机分为试验组和对照组,各45例。对照组给予玻璃酸钠注射液,每次25 mg,每周1次,关节腔内注射,连续注射5次为1个疗程,共治疗2个疗程,疗程之间间隔2周;试验组在对照组的基础上加用洛索洛芬钠片,每次60 mg,每天3次,口服,持续治疗12周。比较2组患者的临床疗效,分析治疗前后2组患者关节滑液中炎症因子[白细胞介素(IL)~(-1)β、IL-6、肿瘤坏死因子(TNF)-α]水平,用视觉模拟评分法(VAS)和西大略湖和麦克马斯特大学(WOMAC)骨关节炎指数评价2组患者疼痛程度和膝关节功能,记录治疗过程中药物不良反应发生情况。结果治疗后,试验组和对照组的总有效率分别为97.78%(44/45例)和82.22%(37/45例),差异有统计学意义(P0.05)。治疗后,试验组IL~(-1)β,IL-6,TNF-α分别为(34.27±5.88),(7.71±2.45),(12.71±3.08)μg·m L~(-1),对照组分别为(45.29±6.18),(11.55±3.00),(16.30±4.13)μg·m L~(-1)(均P0.05)。治疗后,试验组和对照组的VAS评分分别为(2.75±1.01),(3.63±0.94)分(P0.05);WOMAC骨关节炎指数评分分别为(31.51±6.37),(33.85±7.45)分,差异无统计学意义(P0.05)。试验组主要药物不良发应为胃肠道症状和轻微皮疹,药物不良反应发生率为6.67%(3/45例);对照组主要不良发应为胃肠道症状和关节红肿,药物不良发应发生率为11.11%(5/45例),差异无统计学意义(P0.05)。结论洛索洛芬钠联合关节腔内注射玻璃酸钠具有较好的抗炎、镇痛及改善膝关节功能的作用,对骨关节炎具有良好的疗效和安全性。
[Abstract]:Objective To observe the clinical effect of Loxoprofen sodium combined with sodium hyaluronate in the treatment of osteoarthritis (OA). Methods 90 patients with OA were randomly divided into test group and control group. The control group received the sodium hyaluronate injection, each time of 25 mg, once a week, the joint cavity was injected, the continuous injection of 5 times was 1 treatment course, the treatment course was 2 weeks, the course of treatment was 2 weeks, the test group was added with the loxoprofen sodium tablet in addition to the control group, each time of 60 mg,3 times a day, Oral, lasting for 12 weeks. The clinical effect of group 2 patients was compared, and the levels of the inflammatory factors[interleukin (IL) ~ (-1), IL-6, tumor necrosis factor (TNF)-1] in the synovial fluid of the two groups were analyzed. The degree of pain and the function of the knee in the 2 groups were evaluated by the visual analogue scale (VAS) and the University of the West and the McMaster's University (WOMAC) osteoarthritis index in order to record the occurrence of adverse drug reactions in the course of the treatment. Results The total effective rate of the test group and the control group was 97.78% (44/45) and 82.22% (37/45), respectively. After treatment, IL-1, IL-6 and TNF-1 in the test group were (34.27-5.88), (7.71-2.45), (12.71-3.08) & mu; g 路 m-L-(-1), respectively (45.29-6.18), (11.55-3.00), (16.30-4.13). mu.g 路 m-L-(-1) (all P0.05). After the treatment, the VAS scores of the test group and the control group were (2.75-1.01), (3.63-0.94) (P0.05), and the scores of the WOMAC-osteoarthritis index were (31.51-6.37), (33.85-7.45), and the difference was not significant (P0.05). The main drug adverse effects of the test group should be gastrointestinal symptoms and mild rash, and the incidence of adverse drug reactions was 6.67% (3/45); the main adverse effects of the control group should be gastrointestinal symptoms and joint swelling, and the incidence of adverse drug delivery should be 11.11% (5/45), and the difference was not statistically significant (P0.05). Conclusion The injection of sodium hyaluronate in the joint cavity of Loxoprofen sodium has good anti-inflammatory, analgesic and function of improving the function of the knee joint, and has good curative effect and safety for osteoarthritis.
【作者单位】：青海红十字医院疼痛科;
【分类号】：R684.3

【参考文献】